Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tourmaline Bio ( (TRML) ) just unveiled an announcement.
Tourmaline Bio announced key updates at its Investor Day, highlighting progress in its clinical trials and strategic priorities. The company reported over-enrollment in its Phase 2 TRANQUILITY trial and introduced a new indication for pacibekitug, abdominal aortic aneurysm, while planning further developments contingent on trial outcomes, positioning itself for potential expansion in cardiovascular inflammation treatment.
More about Tourmaline Bio
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for life-altering immune and inflammatory diseases. Their lead product, pacibekitug, is a long-acting anti-IL-6 monoclonal antibody with potential applications in atherosclerotic cardiovascular disease and thyroid eye disease, among others.
YTD Price Performance: -3.13%
Average Trading Volume: 233,916
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $650.3M
See more data about TRML stock on TipRanks’ Stock Analysis page.
